Mildronate (Meldonium)

1 capsule of meldonium dihydrate 500 mg

Excipients:

 potato starch - 27.2 mg,

colloidal silicon dioxide - 10.8 mg,

calcium stearate - 5.4 mg.

Capsule shell composition :

titanium dioxide (E171) - 2%,

gelatin - 98%.

Mildronate - cardioprotective, antihypoxic, angioprotective, antianginal.

Under conditions of increased load, Mildronate restores the balance between the delivery and demand of cells for oxygen, eliminates the accumulation of toxic metabolic products in cells, protecting them from damage; has a tonic effect. As a result of its use, the body acquires the ability to withstand stress and quickly restore energy reserves.

Due to these properties, Mildronate is used to treat various disorders of the cardiovascular system, blood supply to the brain, as well as to increase physical and mental performance. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized.

In the case of acute ischemic myocardial damage, Mildronate slows down the formation of a necrotic zone, shortens the rehabilitation period. In case of heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic focus, promotes blood redistribution in favor of the ischemic area. Effective in the case of vascular and dystrophic pathology of the fundus. The drug eliminates functional disorders of the central nervous system in patients with chronic alcoholism with withdrawal symptoms.

Pharmacokinetics

When taken orally, it is well absorbed. Bioavailability is about 78%. Cmax is achieved in 1-2 hours. It is biotransformed in the body with the formation of two main metabolites, which are excreted by the kidneys. T1 / 2 - 3-6 hours and depends on the dose.

• hemophthalmos and retinal hemorrhages of various etiologies;
• thrombosis of the central retinal vein and its branches;
• Ischemic heart disease disorders of cerebral circulation;
• retinopathy of various etiologies (diabetic, hypertensive).

The safety of using the drug during pregnancy has not been established. To avoid possible adverse effects on the fetus, Mildronate should not be prescribed during pregnancy.

It is not known whether meldonium dihydrate is excreted in breast milk. If it is necessary to use the drug Mildronate during lactation, breastfeeding should be discontinued.

• increased intracranial pressure (including in violation of venous outflow, intracranial tumors);
• age up to 18 years (efficacy and safety have not been established);
• pregnancy;
• lactation period (breastfeeding);
• hypersensitivity to the active substance and other components of the drug.

The drug should be used with caution in case of liver and / or kidney diseases.

Mildronate enhances the effect of coronary dilators, some antihypertensive drugs, cardiac glycosides.

Mildronate can be combined with prolonged forms of nitrates, other antianginal drugs, anticoagulants and antiplatelet agents, antiarrhythmics, diuretics and bronchodilators.

In view of the possible development of tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin (for sublingual use) and antihypertensive drugs (especially alpha-blockers and short-acting forms of nifedipine).

In connection with the possibility of the development of an exciting effect, the drug is recommended to be used in the first half of the day and no later than 17.00 (when taken several times a day).

With ischemic heart disease (angina pectoris, myocardial infarction), chronic heart failure as part of complex therapy, the drug is prescribed orally at a dose of 0.5-1 g / day, the frequency of use is 1-2 times / day. The course of treatment is 4-6 weeks.

With dyshormonal cardiomyopathy, Mildronate is administered orally at 500 mg / day as part of complex therapy. The course of treatment is 12 days.

In case of subacute cerebral circulation disorders (stroke and cerebrovascular insufficiency), after the end of the course of injection therapy with Mildronate, they continue to take 0.5-1 g / day as part of complex therapy, using the entire dose once or dividing it into 2 doses. The course of treatment is 4-6 weeks.

In case of chronic disorders of cerebral circulation, the drug is taken as part of complex therapy orally at 0.5 g / day. The general course of therapy is 4-6 weeks. Repeated courses are possible after consulting a doctor (usually 2-3 times a year).

With reduced performance, mental and physical stress (including in athletes), 500 mg is administered orally 2 times / day. The course of treatment is 10-14 days. If necessary, the therapy is repeated after 2-3 weeks.

Athletes are advised to use 0.5-1 g 2 times / day before training. The duration of the course in the preparatory period is 14-21 days, during the competition period - 10-14 days.

With withdrawal symptoms in chronic alcoholism (in combination with specific therapy for alcoholism), the drug is administered orally 500 mg 4 times / day. The course of treatment is 7-10 days.

Symptoms: a decrease in blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: carrying out symptomatic therapy.

Patients with chronic liver and kidney diseases should be careful with prolonged use of the drug.

Use in pediatrics

There is insufficient data on the use of Mildronate in children and adolescents under the age of 18.

Influence on the ability to drive vehicles and control mechanisms

There are no data on the adverse effects of Mildronate on the ability to drive vehicles and mechanisms.

Capsules